The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: Opportunities and challenges

Journal of Clinical Virology

Volumn 30, Issue 3, 2004, Pages 207-210

  Harandi, Ali M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

CpG; Female genital tract; Genital herpes; Herpes simplex virus; Innate immunity; Mucosal immunity

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN B; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; IMIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 18; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; THROMBOSPONDIN; TOLL LIKE RECEPTOR;

CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VACCINATION; VIRUS IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVAGINAL; CPG ISLANDS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNITY, NATURAL; OLIGODEOXYRIBONUCLEOTIDES;

EID: 2442551764     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.03.001     Document Type: Review

References (26)

1. Ashkar A.A., Bauer S., Mitchell W.J., Vieira J., Rosenthal K.L. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol. 77:2003;8948-8956
2. Chen C.Y., Ballard R.C., Beck-Sague C.M., Dangor Y., Radebe F., Schmid S., Weiss J.B., Tshabalala V., Fehler G., Htun Y., Morse S.A. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm. Dis. 27:2000;21-29
3. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas J.M.J., Handsfield H.H., Warren T., Marr L., Tyring S., DiCarlo R., Adimora A.A., Leone P., Dekker C.L., Burke R.L., Leong W.P., Straus S.E. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection. Two randomized controlled trials. JAMA. 282:1999;331-340
4. Garland S.M. Imiquimod. Curr. Opin. Infect. Dis. 16:2003;85-89
5. Gwanzura L., McFarland W., Alexander D., Burke R.L., Katzenstein D. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. J. Infect. Dis. 177:1998;481-484
6. Harandi A.M., Eriksson K., Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J. Virol. 77:2003;953-962
7. Harandi A.M., Svennerholm B., Holmgren J., Eriksson K. Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J. Virol. 75:2001;6705-6709
8. Hartmann G., Weeratna R., Ballas Z., Payette P., Blackwell S., Suparto I., Rasmussen W., Waldschmidt M., Sajuthi D., Purcell R., Davis H., Krieg A. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164:2000;1617-1624
9. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., Zinkernagel R., Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10:2004;187-192
10. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745
11. Karlin S., Doerfler W., Cardon L. Why is CpG suppressed in the genomes of virtually all small eukaryotic viruses but not in those of large eukaryotic viruses? J. Virol. 68:1994;2889-2897
12. Kinghorn G.R. Epidemiology of genital herpes. J. Int. Med. Res. 22:1994;14A-23A
13. Krieg A., Yi A., Matson S., Waldschmidt T., Bishop G., Teasdale R., Koretzky G., Klinman D. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549
14. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:2002;709-760
15. Lazarus R., Klimecki W.T., Raby B.A., Vercelli D., Palmer L.J., Kwiatkowski D.J., Silverman E.K., Martinez F., Weiss S.T. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics. 81:2003;85-91
16. Naesens L., De Clercq E. Recent developments in herpesvirus therapy. Herpes. 8:2001;12-16
17. Parr M.B., Kepple L., McDermott M., Drew M.D., Bozzola J.J., Parr E.L. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab. Invest. 70:1994;369-380
18. Parr M.B., Parr E.L. Vaginal immunity in the HSV-2 mouse model. Int. Rev. Immunol. 22:2003;43-63
19. Pyles R.B., Higgins D., Chalk C., Zalar A., Eiden J., Brown C., Van Nest G., Stanberry L.R. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J. Virol. 76:2002;11387-11396
20. Schacker T.W., Conant M., Thoming C., Stanczak T., Wang Z., Smith M. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study. Antimicrob. Agents Chemother. 46:2002;3243-3248
21. Stamm W.E., Handsfield H.H., Rompalo A.M., Ashley R.L., Roberts P.L., Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA. 260:1988;1429-1433
22. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., Tyring S., Aoki F.Y., Slaoui M., Denis M., Vandepapeliere P., Dubin G. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:2002;1561-1652
23. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y., Furutani Y., Yano O., Kataoka T., Sudo T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72:1984;955-962
24. Tokunaga T., Yamamoto T., Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn. J. Infect. Dis. 52:1999;1-11
25. Whitley R.J. Perinatal herpes simplex virus infections. Rev. Med. Virol. 1:1991;101-110
26. Yi A.-K., Chang M., Peckham D., Krieg A., Ashman R. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 160:1998;5898-5906